Heng Rui Medicine spy door alarmed FBI two suspect is a company executive

Heng Rui Medicine, known for its innovative medicine (600276). SH) recently fell into the "spy Door" storm. According to the U.S. Federal Court of Justice, including Heng Rui Medical employees three of natural persons accused of stealing the United States well-known drug companies to pharmaceutical value of 55 million U.S. dollars of trade secrets, about 340 million yuan. The complaint revealed that the three suspects were former Lilly employees guogqing Cao and Shuyu Li, as well as another unnamed suspect who works for Heng Rui Medicine. According to the 21st Century Network survey found that Heng Rui Pharmaceutical current biological research and development deputy general Manager Cao's Hanyu Pinyin name and Guoqing Cao the same, and Shuyu Li is suspected of Lilly (China) Research and Development Co., Ltd. former executive director Li Dan (sound). Heng Rui Medicine is not the first time and Lilly Pharmaceutical Festival. As early as 2000, Eli Lilly sued the pharmaceutical for patent infringement. In recent years, Heng Rui Medicine is committed to the field of diabetes drugs to seek breakthroughs, many times from the specialty of diabetes drugs to pharmaceutical "digging horns", both sides can be described as "deep grievances." Under US law, a firm is liable to a fine of 10 million dollars if it is confirmed to be engaged in commercial espionage. The lawyer pointed out that this "spy door" incident or will have a negative impact on the domestic and foreign business of Heng Rui Medicine. Heng Rui stolen U.S. trade secrets alerted the FBI indictment two Chinese-Americans, named Guoqing Cao and Shuyu Li, a former pharmaceutical scientists, involved in a total of seven counts of theft and conspiracy to steal. According to the indictment, Guoqing Cao and Shuyu Li copied proprietary information on the development of diabetes, heart disease and cancer drugs to an external hard drive and sent e-mails containing trade secrets multiple times. The indictment also accuses a former employee of a Lilly pharmacy who is now working for the people of Heng Rui Medicine. However, the indictment did not disclose its name, only described in "character 1". According to media reports, Guoqing Cao and Shuyu Li were arrested on October 1 and subsequently dressed in handcuffs and jumpsuit in Indianapolis District Court. The leak has alarmed the FBI. According to the FBI internal personnel, the case of Heng Rui Medicine in the "character 1" is still under investigation, has not been arrested. The above news, after the public opinion, Heng Rui Medicine October 9 Evening issued an emergency clarification announcement, said the company did not receive any legal documents in the domestic and foreign jurisdictions, also said that the company does not exist any violation of the applicable law requirements. Currently guoqing Cao and Shuyu Li have been held in custody until the trial by the District Court. 21st Century Network October 9 several times to call Heng Rui Medicine to understand the situation, but the telephone has never been answered. Affected by this news, Heng Rui Medicine shares October 10 low drive low, close to 34.06 yuan/share, down 3.79%, significantly weaker than the market. Heng Rui Current senior management suspect in the 21st century network investigation found that one of the perpetrators of English named Guoqing Cao, with the 2012 just enteredCao, deputy general manager of Pharmaceutical biology research and development, has the same phonetic name. At the same time, Cao has a working background of American courtesy. Cao's resume shows that he received a Ph. D. in biochemistry from Ohio State University in 1995, and in 1995-1999, the Southwestern Medical Center of the University of Texas was awarded Michael Brown,joseph, a Nobel laureate in physiology and medicine. Dr. Goldstein and Professor Helen Hobbs of the National Academy of Sciences are engaged in cholesterol metabolism and cardiovascular disease research. Cao joined the United States in 1999 as a senior biologist in the Department of Cardiovascular and Metabolic disease, and was promoted to lead scientist in 2002, and was promoted to research advisor and Senior Research Advisor in 2006 and 2008. Cao in the ceremony to pharmaceutical during the academic achievements, has received the ceremony to develop the highest award research and Development President Award, in the influential magazine published more than 70 articles. 2012, Cao was a deputy general manager of biology research and development, and was responsible for the strategy and research and development of new drug research. From the Cao curriculum vitae, not only does his experience conform to the description of the suspect Guoqing Cao in the United States Federal Court pleadings, but also its stolen secrets are in the same subject area as Cao's expertise, and Cao's name is in line with the name of the suspect in the pleadings. So "coincidence" is amazing. 21st Century Network 9th many times to call Heng Rui Medicine to try to verify the relevant situation, but its phone are in no answer to the state. Shuyu Li, a former executive director of the Chinese company, has been suspected of being a suspect at the end of the ceremony, while the other is an Li Dan. On the 20-page indictment of the Federal Court, Shuyu Li's full name is actually Shuyu "Dan" Li. According to the 21st Century Network survey, Shuyu "Dan" Li for Lilly (China) Research and Development Co., Ltd., the former executive director. This is consistent with the propriety of the pleadings. At the end of May 2013, Shuyu "Dan" Li attended the 15th Shanghai International Symposium on Biotechnology and Medicine and published a speech on the genome-wide sequencing of the genetic mechanism of liver cancer. The 21st Century network consulted the seminar's list of experts and found that the name of the Shuyu "Dan" Li Chinese presentation page was shown as "Dan Li" (Li Dan). It is clear that Li Dan not only served in the pharmaceutical industry, but also in the field of liver cancer experts. At the same time, Lilly China Research and Development Co., Ltd. is one of the areas focused on the development of diabetes-related drugs. The two areas of medicine, which fall within the scope of the stolen secret, are again in line with the pleadings. 21st Century Network 10th called the Chinese Research and development company to inquire about Li Dan, its staff said it "has been out for a period of time", but the Li Dan is due to spy "" "and leave, the staff said" can not comment on the matter. " Heng Rui and the ritual come early has the festival Heng Rui Medicine in the domestic alwaysRenowned for its ability to innovate, it has now collapsed into the "spy door" and shocked the industry, leaving its reputation for "innovation" a lot of luster. In fact, Heng Rui Medicine is not the first time with Lilly Pharmaceutical "fight", two pharmaceutical giants have a long time to celebrate. 2000, Lilly Pharmaceutical with Heng Rui medicine to invade its cancer drugs, gemcitabine patent for the case of Heng Rui Medicine to court, after 7 years of trial, the court finally decided that the case of Gemcitabine patent invalid, Lilly to the pharmaceutical. And anti-tumor drugs have become the star products of Heng Rui Medicine now. According to Heng Rui Medicine 2012 annual report showed that the company's drug sales in the domestic number one, market share reached more than 12%. The Heng Rui Medicine and Lilly Pharmaceutical through the "spy door" to play again, or from the weak point of Heng Rui Medicine-diabetes drugs, and this area is the strength of Lilly Pharmaceutical. It is understood that Heng Rui Medicine in anti-tumor drugs, surgery, endocrine therapy drugs, cardiovascular drugs have a strong competitiveness, but in the development of diabetes drugs is not very good. According to media reports, 2009 China's high-end diabetes drugs market share of 95% by the three foreign pharmaceutical companies, including Eli, divided up. In fact, Heng Rui Medicine has been developed in the past 2009 years for the treatment of type II diabetes innovative drugs-Rui Sitagliptin, and was approved in the United States to enter a clinical trial, this is the first time in the chemical industry in the United States to carry out clinical trials of innovative drugs, the industry has high expectations. Anxious to make breakthroughs in the field of diabetes drugs, Heng Rui Pharmaceutical will look at the ritual to the pharmaceutical "corner." 2009, Heng Rui Medicine will be Lilly Pharmaceutical chief scientist Zheng Yuqun "dug" to the company as deputy general Manager, in 2010, he also served in the ceremony for more than 10 years of the chief Scientist Zhanglianxian into under the command of deputy general manager. "Digging the Corner" is not a big effort. It is understood that Zheng Yuqun has recently left the medical service from Heng Rui, and Zhanglianxian's main task is "to establish an international leading diabetes innovative drug research and development system." Heng Rui Medicine 2013.5 Annual report shows that the company for type II diabetes has developed a new drug furosemide pan, and recently approved in the United States to carry out phase I clinical trials. However, today, Heng Rui Pharmaceutical Rui Sitagliptin and the tablets are still not listed in the Domestic diabetes drug market is still in a state of absence. A maximum of 10 years in prison. Heng Rui Medicine is actively exploring the European and American markets, and in the United States with innovative drug research center. Senior lawyers in the industry believe that the "spy door" incident or will have a negative impact on their domestic and foreign business. Under United States law, a person convicted of stealing trade secrets can be sentenced to 10 years ' imprisonment or a fine of 250,000 US dollars, and if he is identified as a commercial agent, the individual can be sentenced to 15 years ' imprisonment or a 500,000 dollar fine, while a corporate crime is punishable with a maximum penalty of 10 million dollars. Xu Feng, a practising lawyer for Shanghai Huarong law firm, said in 21st century that a company with a criminal record would be deemed to have a problem with integrity, which would have a negative impact on the company's business development. "Business practices in certain areas are not allowed to have criminal records," Xu Feng said., so criminal companies may be barred from doing certain business. "Judgments from abroad may also affect domestic business," he said. Xu Feng said that even if the court's decision could not be enforced in the country where the judgment was in force, such as when the criminal enterprise was not in a position to pay the penalty in the effective state, the ruling state could also request assistance from the State of the enterprise through diplomatic channels. "The basic view is that the company's business development must be adversely affected." "In recent years, the United States for the Chinese enterprises" spy "survey is rising, spy case is distributed in communications, automobiles, futures, medicine, chemistry, food and other industries. For the constant Rui medicine "Spy Gate" the follow-up progress of the incident, 21st century network will continue to maintain concern.